Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Foghorn Therapeutics Inc (NQ: FHTX )

6.840 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 6.840
Bid (Size) 5.520 (1)
Ask (Size) 10.49 (1)
Prev. Close 6.840
Today's Range 6.840 - 6.840
52wk Range 2.700 - 9.970
Shares Outstanding 36,936,886
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
From Foghorn Therapeutics, Inc.
Via GlobeNewswire

Performance

YTD
+6.05%
+6.05%
1 Month
+17.12%
+17.12%
3 Month
+19.37%
+19.37%
6 Month
+82.40%
+82.40%
1 Year
-25.33%
-25.33%

More News

Read More
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics: Q4 Earnings Insights
Via Benzinga
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Misses Revenue for Q1 2024
Via InvestorPlace
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023
Via InvestorPlace
Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Foghorn Therapeutics (FHTX) Stock Is Exploding Higher
Via Benzinga
Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Announces CFO Departure
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics to Present Clinical and Pre-Clinical Data from Multiple Programs Across Its Diverse Pipeline at AACR-NCI-EORTC International Conference
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Foghorn Therapeutics Announces Participation in Upcoming Investor Conferences
From Foghorn Therapeutics, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.